233
Participants
Start Date
August 27, 2013
Primary Completion Date
May 18, 2018
Study Completion Date
March 6, 2019
Selumetinib
3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
Placebo
3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
Radioactive Iodine Therapy
A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
Research Site, Odense C
Research Site, New York
Research Site, New York
Research Site, Philadelphia
Research Site, Washington D.C.
Research Site, Durham
Research Site, Toulouse
Research Site, Bordeaux
Research Site, Birmingham
Research Site, Caen
Research Site, Essen
Research Site, Cincinnati
Research Site, Angers
Research Site, Pisa
Research Site, Little Rock
Research Site, Aurora
Research Site, Napoli
Research Site, Augsburg
Research Site, Los Angeles
Research Site, Torrance
Research Site, Villejuif
Research Site, Catania
Research Site, Portland
Research Site, Boston
Research Site, Boston
Research Site, Nashville
Research Site, Barretos
Research Site, Porto Alegre
Research Site, Ribeirão Preto
Research Site, Rio de Janeiro
Research Site, São José do Rio Preto
Research Site, São Paulo
Research Site, Lyon
Research Site, Leipzig
Research Site, Roma
Research Site, Gliwice
Research Site, Kielce
Research Site, Poznan
Research Site, Warsaw
Research Site, Warsaw
Research Site, Zgierz
Research Site, Gothenburg
Research Site, Linköping
Research Site, Lund
Research Site, Stockholm
Lead Sponsor
AstraZeneca
INDUSTRY